Janux Therapeutics Q4 net loss widens on higher R&D expenses

Overview

• Biopharmaceutical firm's Q4 net loss widened due to increased R&D expenses

• Company reported strong year-end cash position to support pipeline execution

Result Drivers

• STRATEGIC COLLABORATION - Collaboration with Bristol Myers Squibb provides capital and validates Janux's platform, with potential for milestone payments and royalties

• CASH POSITION - Strong year-end cash position supports continued pipeline execution

Company press release: ID:nBw3cHvrVa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Janux Therapeutics Inc is $53.50, about 290.5% above its February 25 closing price of $13.70

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.